- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Connect with us:
Latest from Cleveland Clinic
Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
November 05, 2025
Podcast
Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.
Five Under 5: Top Oncology Videos for the Week of 10/26
November 02, 2025
Article
The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.
Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis
October 21, 2025
Video
Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.
BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards
October 21, 2025
Article
Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.
Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis
October 14, 2025
Video
Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.
Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment
October 13, 2025
Article
Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.
Five Under 5: Top Oncology Videos for the Week of 10/5
October 12, 2025
Article
The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.
ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology
October 09, 2025
Article
Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.
Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis
October 08, 2025
Video
Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.
Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis
October 07, 2025
Video
Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.
Talquetamab/Teclistamab May Address Need for Improved Survival Outcomes in R/R Myeloma With Extramedullary Disease
August 25, 2025
Article
Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.
Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
July 22, 2025
Article
Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.
Five Under 5: Top Oncology Videos for the Week of 6/29
July 06, 2025
Article
The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.
OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025
July 01, 2025
Article
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
Five Under 5: Top Oncology Videos for the Week of 6/8
June 15, 2025
Article
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer
May 16, 2025
Video
Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.
Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes
April 30, 2025
Article
Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.
Dr Ali on the Potential SOC Role of Palbociclib Plus Anti-HER2 and Endocrine Therapy in HER2+ Breast Cancer
April 24, 2025
Video
Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.
Dr Gupta on Avelumab Maintenance Therapy in Advanced Urothelial Cancer With Diabetes
March 21, 2025
Video
Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.
Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer
February 25, 2025
Article
Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.